Another Phase I trial involved administration of a lipid-coated mRNA-4157 that encodes for a wide range of tumour antigens to elicit tumour responses independently, as well as in combination with the anti-PD1 humanized antibody pembrolizumab. This evidence concerns the gene PDCD1 and neoplasm.